VEGFA and glioma: Periostin (POSTN), a canonical osteoblast marker, has not only exhibited a most significant declination among the whole collection, but recent study has also already verified hypothesis that aberrant stimulation of it concerned with bevacizumab induced resistance in the cases of glioma implementing with anti-VEGF-A therapy17.